Literature DB >> 29459454

Journal Club: MRI reveals acute inflammation in cortical lesions during early MS.

Emily M Bateman1, Wolfgang E Schleicher1, Elana J Smith1, David R Sweet1, Andrew D Gaudet2.   

Abstract

Early multiple sclerosis is characterized by immune-associated demyelination of CNS axons. In a recent Neurology® article, Maranzano et al. evaluated MRI scans of patients with early multiple sclerosis to study the evolution of leukocortical lesions. Their novel data suggest that acute inflammation after blood-brain barrier leakage may contribute to gray matter cortical lesions in early multiple sclerosis.
© 2018 American Academy of Neurology.

Entities:  

Mesh：

Year:  2018        PMID： 29459454      PMCID： PMC5818168          DOI： 10.1212/WNL.0000000000005001

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 2.  Exploring the origins of grey matter damage in multiple sclerosis.

Authors:  Massimiliano Calabrese; Roberta Magliozzi; Olga Ciccarelli; Jeroen J G Geurts; Richard Reynolds; Roland Martin
Journal:  Nat Rev Neurosci       Date:  2015-03       Impact factor: 34.870

3.  Gray matter atrophy in multiple sclerosis: a longitudinal study.

Authors:  Elizabeth Fisher; Jar-Chi Lee; Kunio Nakamura; Richard A Rudick
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

4.  Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.

Authors:  D Cadavid; L J Wolansky; J Skurnick; J Lincoln; J Cheriyan; K Szczepanowski; S S Kamin; A R Pachner; J Halper; S D Cook
Journal:  Neurology       Date:  2009-03-11       Impact factor: 9.910

5.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

6.  Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis.

Authors:  Massimiliano Calabrese; Nicola De Stefano; Matteo Atzori; Valentina Bernardi; Irene Mattisi; Luigi Barachino; Aldo Morra; Luciano Rinaldi; Chiara Romualdi; Paola Perini; Leontino Battistin; Paolo Gallo
Journal:  Arch Neurol       Date:  2007-10

7.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.

Authors:  M Filippi; T Yousry; A Campi; C Kandziora; B Colombo; R Voltz; V Martinelli; S Spuler; S Bressi; G Scotti; G Comi
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

Review 8.  Meningeal and cortical grey matter pathology in multiple sclerosis.

Authors:  Bogdan F Gh Popescu; Claudia F Lucchinetti
Journal:  BMC Neurol       Date:  2012-03-07       Impact factor: 2.474

9.  MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.

Authors:  Josefina Maranzano; David A Rudko; Kunio Nakamura; Stuart Cook; Diego Cadavid; Leo Wolansky; Douglas L Arnold; Sridar Narayanan
Journal:  Neurology       Date:  2017-07-19       Impact factor: 9.910
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.